GPR119 Agonist Compounds for Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus, such as weight loss, healthy diet, and exercise, are not effective for controlling the condition, and existing medications have drawbacks like hypoglycemic episodes, weight gain, gastrointestinal issues, and reduced responsiveness over time.
Innovation Solution
Development of novel compounds that act as GPR119 agonists, specifically activating the G protein-coupled receptor GPR119 to enhance glucose-dependent insulin secretion and GLP-1 release, thereby improving glucose tolerance without causing hypoglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for type 2 diabetes (weight loss, healthy diet, exercise) are used, then lifestyle factors are addressed, but they are not effective for controlling diabetes mellitus itself
Solution Approach 1:
The patent introduces a novel chemical compound with a specific molecular structure (formula I) that activates GPR119 receptors. This represents a fundamental parameter change from lifestyle modifications to a pharmacological intervention with defined chemical properties, achieving reliable glucose control while maintaining ease of administration as a simple oral medication.
2Reliability
If existing diabetes medications are used, then glucose control is achieved, but side effects occur including hypoglycemic episodes, weight gain, gastrointestinal problems, and edema
Solution Approach 1:
The patent exploits the GPR119 receptor pathway, which is naturally expressed in pancreatic beta cells and gut L-cells. By activating this endogenous pathway with a selective agonist, the treatment converts normal physiological processes into therapeutic benefit, producing glucose-dependent insulin secretion and GLP-1 release without the harmful side effects of conventional medications.
Solution Approach 2:
The GPR119 receptor acts as an intermediary between the administered compound and the downstream effects on insulin secretion and GLP-1 release. The compound selectively binds to and activates GPR119, which then mediates the beneficial effects through cAMP-dependent pathways, providing a targeted mechanism that avoids the non-specific side effects of other diabetes medications.
3Reliability
If existing diabetes medications are used, then initial glucose control is achieved, but loss in responsiveness to therapy occurs over time
Solution Approach 1:
The patent describes a compound that dynamically activates GPR119 receptors in a glucose-dependent manner. The therapeutic effect is not static but adapts to physiological glucose levels, providing sustained responsiveness by coupling drug action to the body's natural glucose metabolism cycles rather than providing fixed-dose stimulation that leads to tolerance.
4Reliability
If GPR119 agonists are developed to enhance glucose-dependent insulin secretion, then glucose tolerance improves without hypoglycemia, but novel compounds with appropriate pharmacological properties are needed
Solution Approach 1:
The patent presents a segmented molecular structure (formula I) with distinct substituents (R1, R2, R3, R4, R5, R6, R7, R8) that can be independently optimized. This segmentation allows for systematic structure-activity relationship studies and rational drug design, facilitating the development of compounds with desired pharmacological properties while streamlining the manufacturing process through modular synthesis approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate significant dose-dependent glucose reduction in animal models and active GLP-1 secretion, offering an effective treatment for type 2 diabetes mellitus with improved safety profiles compared to existing therapies.
Implementation Method 1
Activation of GPR119 has been demonstrated to stimulate intracellular cAMP and lead to glucose dependent GLP-1 and insulin secretion
Data Source
AI summary
The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.